360 results about "Targeting therapy" patented technology

The invention discloses a skin targeted therapy laser control method and system based on a dual-wavelength synergistic effect, and the method comprises the steps: collecting the real-time morphological characteristics and pigment distribution data of skin tissues through a multispectral imaging unit, and recognizing the optical characteristic parameters of a target treatment region; generating a dual-wavelength combination scheme through a dynamic wavelength selection algorithm based on the optical characteristic parameters and the tissue structure characteristics of the target treatment area; according to a dual-wavelength combination scheme, generating a synergistic laser sequence with a specific pulse interval and energy ratio; the synergistic laser sequence is converted into a driving signal, and a dual-wavelength laser is controlled to output composite laser; and laser output parameters are dynamically adjusted through real-time thermal diffusion monitoring and an optical feedback mechanism. By utilizing the embodiment of the invention, accurate and selective heat dissipation of skin target tissues can be realized, surrounding normal tissues are effectively protected, the treatment safety and effectiveness are improved, and side effects are reduced.

The invention provides an antibody drug conjugate property prediction method based on multi-modal fusion, and belongs to the field of bioinformatics. The method comprises the following steps: firstly, explicitly modeling sequence position information through sine position coding; secondly, introducing a bidirectional cross attention mechanism to establish interaction between a light chain and a heavy chain and alignment between an antigen and an antibody; thirdly, the integrated graph neural network reconstructs the adjacency relation according to the attention weight, and topological features are extracted; and finally, in combination with a double-stage self-adaptive refining module, two-stage treatment of alignment and refining is realized, and each modal feature contribution is adjusted in a self-adaptive manner. And meanwhile, the sequence robustness is improved through Mask perception feature extraction, and the interpretability analysis of the key binding sites is realized through the attention weight. The method can significantly improve the prediction accuracy, and can be widely applied to cancer targeted therapy and drug design optimization.

The invention discloses an application of imatinib mesylate in preparation of a targeted therapeutic drug for gastric signet ring cell carcinoma. The imatinib mesylate has an obvious inhibition effect on the growth of six patients with the pathological type of gastric signet-ring cell carcinoma, the inhibition effect is more obvious along with the increase of the concentration, the concentration and dosage dependency relationship is shown, and the half inhibitory concentration (IC50) is obviously smaller than that of a positive control drug apatinib. The medicine can play a targeted therapeutic role on the gastric signet ring cell carcinoma, and is small in toxic and side effects, economical, practical and low in cost.

Described are devices and methods for administering targeted ultrasound therapy. The device consists of a wearable housing designed to conform to a part of the user's body, with an array of ultrasound transducer units on the skin-facing side. These transducers can generate ultrasound therapy to a target therapy area of the user, with frequency, intensity, treatment area, and duration parameters optimized for a therapeutic application. Incorporated within the device is a communication system, an energy source, and a processor. The processor's role is to execute instructions, including assessing the user's health status based on received data, processing and analyzing ultrasound data to gauge transmission quality, determining if the current transmission quality is within thresholds, initiating ultrasound therapy when the conditions are right, and adjusting ultrasound therapy parameters real-time or near real-time if needed during treatment. The real-time or near real-time adjustment is made through various parameters like pulsing frequency, pulse train frequency, the number of treated spots, duration, and treatment zone area. This device provides a personalized, adaptive approach to ultrasound therapy, optimizing the treatment process for each individual user.

The invention relates to the technical field of biology, and provides a genetic marker for children nephrotic syndrome genetic risk assessment. The invention relates to genetic detection and application of hormone sensitive nephrotic syndrome (pSSNS) of children. Nine risk sites, including new sites of 1q23.1, 1p36.13, 5p13.2, 10q21.3, 10q24.1 and the like, highly related to diseases are found by integrating whole genome association research (GWAS) data, combining Meta analysis and a conjugate false discovery rate (conjFDR) method and taking genetic information of IgA nephropathy as assistance. Research results show that genes near the loci have differential expression in pSSNS and IgAN patients, which prompts that the genes play an important role in the occurrence and development of diseases. The invention provides a molecular detection method based on the risk site, which can be used for risk assessment, auxiliary diagnosis and prognosis prediction of children's nephropathy. Meanwhile, the invention provides potential application values of the loci and related genes thereof in individualized medication and targeted therapy.

The invention discloses a solid lipid nanoparticle-inulin gel compound for targeted therapy of ulcerative colitis and a preparation method of the solid lipid nanoparticle-inulin gel compound, and belongs to the technical field of medicines, the compound comprises inulin gel and solid lipid nanoparticles dispersed in the inulin gel; the solid lipid nanoparticle comprises a glyceride shell, oleic acid coated by the glyceride shell, a medicine with anti-inflammatory and anti-oxidation effects, and cationic lipid, the mass ratio of the oleic acid to the medicine with the anti-inflammatory and anti-oxidation effects to the cationic lipid is 1: (1-1.5): (2.5-3); the drug loading capacity in the solid lipid nanoparticles is 1 to 10 weight percent. According to the compound, the inulin gel serves as a delivery system, functional solid lipid nanoparticles are carried in the compound, intestinal ferroptosis can be reduced, active oxygen can be removed, the compound has the effects of promoting intestinal barrier repair, relieving inflammatory response and the like, and the compound has good application prospects in the aspect of treatment of ulcerative colitis.

A cage-like nanocarrier for targeted delivery of siRNA, and a preparation method therefor and the use thereof. The preparation method comprises: (A) mutating a negatively charged or uncharged amino acid on the inner surface of a ferritin into a positively charged amino acid; and any one or more of the following steps: (B) coupling the N-terminus of the ferritin to a functional peptide having nucleic acid affinity; (C) coupling the N-terminus of the ferritin to a functional peptide promoting lysosomal escape; (D) truncating the E-helix at the C-terminus of the ferritin; (E) coupling the C-terminus of the ferritin to a functional peptide having nucleic acid affinity; and (F) coupling the C-terminus of the ferritin to a functional peptide promoting lysosomal escape. A new nucleic-acid-loaded protein nanocage carrier is constructed by means of modifying a negatively charged inner cavity of ferritin to make same positively charged. By means of electrostatic adsorption, a negatively charged siRNA can be efficiently loaded into a ferritin nanocage, thereby significantly improving the in-vivo and in-vitro delivery stability of siRNA, lysosomal escape functions, and efficacy of targeted therapy.

A method for determining if an agent is suitable for treating a Rheumatoid Arthritis (RA) patient, the method comprising determining the profile of a first, second and / or third marker panel in a sample from the patient, wherein the agent is selected from an agent that downregulates TNF mediated signalling, an agent that downregulates IL-6 mediated signalling and a B cell targeted therapy.

The invention discloses a preparation method of hydroxyapatite-artificial bear gall powder nanoparticles, the preparation method comprises the steps of preparing hydroxyapatite nanoparticles and loading artificial bear gall powder, the preparation method is simple and easy to implement, mild in condition and suitable for drug loading, and the preparation method is suitable for large-scale industrial production. The prepared nano-particles have good biocompatibility, degradability, high safety, high stability and high aqueous medium dispersibility, and due to the stability, the nano-particles can realize long-time circulation of drugs in vivo and avoid premature removal of the drugs, so that the bioavailability of the drugs is improved; the obvious pH-responsive slow release of the artificial bear gall powder can be realized, so that the artificial bear gall powder can be used in targeted therapy; compared with other carrier materials, the adopted raw materials are low in price, do not contain metal, have great advantages in cost and environmental protection, are easier to realize large-scale industrial production, and have good application prospects.

The invention discloses a design method and application of a tyrosinase (TYR) responsive drug for targeted therapy of melanoma, and belongs to the technical field of biological medicines. Based on the biological mechanism that TYR catalyzes tyrosine oxidation, a self-degradation connecting arm drug release strategy is combined, a similar 3-hydroxybenzyl alcohol structure is introduced to simulate a tyrosine substrate, specific recognition and activation of TYR on the drugs are achieved, and the problems that traditional chemotherapeutic drugs are poor in targeting property and serious in adverse reaction are hopefully solved.

An ultrasound therapy device for generating ultrasound therapy. The ultrasound therapy device includes a wearable structure, ultrasound transducer units, a tightening mechanism, a memory, and a processor. The wearable structure is securable to a user to transmit the ultrasound to a target therapy area of a user including at least one of a kidney region, a lung region, and a lower limb of the user. The ultrasound transducer units are attachable and repositionable in the wearable structure to generate and deliver the ultrasound to the target region. The ultrasound transducer units are arranged in an array. The array of ultrasound transducer units is mechanically moved within the wearable structure and is in contact with a material to facilitate penetration of ultrasound into the user's body.

The invention relates to a radionuclide labeled trimer probe 68Ga-TRAP-(FAPI) 3 targeting FAP and a preparation method thereof, Trap is used as a trivalent chelating platform, and three FAPI targeting units are covalently connected by clicking a chemical linking arm to form a trimer structure; the invention further relates to application of the 68Ga-TRAP-(FAPI) 3 probe in preparation of imaging agents or therapeutic drugs for diagnosing FAP positive diseases, experiments prove that the trimer probe is good in affinity and high in stability, and in cell experiments and animal experiments, the uptake rate of FAP positive cells is kept at a high level within 240 minutes; preclinical and preliminary clinical applications show that the tumor detection rate of the < 68 > Ga-TRAP-FAPI 3 in various cancer models is superior to that of < 18 > F-FDG, and compared with < 68 > Ga-FAPI-04, the < 68 > Ga-TRAP-FAPI 3 is clearer to display focuses (particularly tiny metastases), higher in uptake intensity and particularly outstanding in delayed imaging, and the < 68 > Ga-TRAP-FAPI 3 can be used for preparing a medicine for treating cancer. And a novel drug candidate with better performance is provided for precise diagnosis and staging of tumors and subsequent radionuclide targeted therapy.

The invention discloses a magnetic-aptamer targeting tumor tissue nano-drug delivery system as well as a preparation method and application thereof, and belongs to the field of medicines. The system comprises a mesoporous ferroferric oxide magnetic core, a polyethyleneimine (PEI) layer coated outside the mesoporous ferroferric oxide magnetic core and an aptamer adsorbed outside the PEI layer, and an autophagy activator can be selectively loaded in the mesoporous core. The preparation method comprises the following steps: sequentially carrying out drug loading, PEI coating and aptamer modification on the mesoporous Fe3O4 nanoparticles. According to the invention, efficient enrichment and endocytosis of tumor tissues are realized through dual effects of magnetic targeting and active targeting of the aptamer; lysosome escape is promoted by using the proton sponge effect of PEI; finally, by virtue of the synergistic effect of iron ions released by degradation of the Fe3O4 nanoparticles and endogenous iron ions released by ferritin autophagy induced by an autophagy activator, ferroptosis of tumor cells is induced through enhanced Fenton-like reaction, so that high-efficiency and low-toxicity targeted therapy is realized.

The invention relates to the technical field of biochemistry, and particularly discloses a galactosyl zinc-porphyrin derivative and a preparation method and application thereof.The galactosyl zinc-porphyrin derivative is formed by coupling a group with double functions of fluorescence and cytotoxic activity and a liver cancer targeting group, can be specifically combined with a liver cancer cell HepG2, emits 608 nm and 659 nm fluorescence signals under the excitation wavelength of 425 nm, and can be used for detecting liver cancer. And accurate tracing can be realized. Meanwhile, IC509.1 mu M + / -2.59 is used for killing liver cancer cells, so that targeted therapy is realized. The chemical disclosed by the invention has the functions of fluorescence tracing and targeted killing, can synchronously realize accurate positioning (fluorescence tracing) and efficient removal (targeted treatment) of liver cancer cells without drug combination, can be used for liver cancer diagnosis, treatment and curative effect evaluation, and has extremely high research and development value.

The invention relates to the technical field of tumor molecular imaging, nuclear medicine diagnosis and targeted therapy, and discloses a Trop2-targeted polypeptide, a Trop2-targeted molecular probe and application of the Trop2-targeted polypeptide and the Trop2-targeted molecular probe. The polypeptide can be coupled with different imaging elements to construct molecular probes or radiopharmaceuticals for tumor targeted imaging, so that noninvasive visual detection on the Trop2 expression level in tumor tissues is realized. The probe can specifically recognize Trop2 positive solid tumors, and a new technical means is provided for noninvasive diagnosis and dynamic monitoring of various Trop2 high-expression tumors such as pancreatic cancer, lung cancer, breast cancer and thyroid cancer. The probe disclosed by the invention has the advantages of simple preparation process, low cost, high specificity and stability, short imaging period, low radiation dosage, easiness in clinical transformation and the like, and has a wide application prospect in precise diagnosis and individualized treatment of tumors.

The invention provides an anti-CD16a single-domain antibody and an application of the anti-CD16a single-domain antibody. In particular, the invention provides a specific single domain antibody for resisting human CD16a. The invention also provides a coding sequence for coding the single-domain antibody or the VHH chain thereof, a corresponding expression vector, a host cell and a method for producing the single-domain antibody. The single-domain antibody provided by the invention has high affinity and high specificity, and can be used for detection and targeted therapy of CD16a.

This invention discloses a lipid assembly loaded with 5-aminolevulinic acid and its preparation method. The lipid assembly is a hollow sphere with a core consisting of a hydrophilic phospholipid-chelating agent conjugate formed by chelation with a reactive phospholipid PEG reagent. The outer layer of the phospholipid-chelating agent conjugate is loaded with 5-aminolevulinic acid via hydrazone bonds, and then combined with a radionuclide as an internal light source excitation photosensitizer. The lipid assembly is loaded with 5-ALA via hydrazone bonds. Utilizing the acid-sensitive bond-breaking characteristics of hydrazone bonds and the prodrug properties of 5-ALA, combined with a radionuclide labeled on the surface of the lipid assembly as an internal light source excitation photosensitizer, this invention can overcome the limitations of external light penetration depth in traditional photodynamic therapy, achieving deep PDT treatment. Combined with chemotherapy drugs, it can minimize the toxic side effects on normal tissues during the combined use of radionuclides and photosensitizers in targeted therapy.

The invention belongs to the field of pathologies affecting the central nervous system: in particular, severe cerebral pathologies, more particularly those restricted by the presence of the blood-brain barrier (BBB): gliomas, cerebral metastases, neurodegenerative diseases (e.g. Alzheimer's, Parkinson's or ALS), genetic diseases (Huntington's, myopathies, Leigh syndrome, Rett syndrome), but also to the field of cancers, musculoskeletal and immunological disorders, vascular diseases (thrombus) in numerous organs (e.g. liver, kidney or muscle) and in combination with numerous therapeutic approaches (e.g. chemotherapy, immunotherapy, targeted therapy or gene therapy). The invention relates to a microbubble comprising a fluorinated polymer or copolymer and a fluorinated gas, to the use thereof and also to the polymer or copolymer intermediate compounds.

Systems and methods for destroying or inhibiting cancer cells and other rapidly-dividing cells including an alternating polarity (AP) magnetic field generator and one or more AP electromagnetic coil adapted to be coupled to at least a portion of a patient's body, and a controller to control the AP magnetic field generator and at least one AP electromagnetic coil and cause the field generator and coil to apply AP magnetic field having a frequency of 0.5-500 KHz and a field strength of 0.5-5 mT to the at least a portion of the patient's body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer therapy such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, an angiogenesis inhibitor drug, or tumor treatment field therapy.

The application provides a nanobody targeting human transmembrane activator and calcium modulator and cyclophilin interactor (TACI) and an application thereof, and the antibody is derived from a llama heavy chain antibody variable region. The anti-TACI single-domain antibody NB38 can specifically bind to human TACI with high affinity, can recognize a recombinant TACI protein, can also recognize a TACI with a natural conformation on a cell surface, and can partially block a BAFF / APRIL signal pathway. Based on the nanobody, the application constructs a fusion protein, a chimeric antigen receptor, an effector cell expressing the chimeric antigen receptor, and a double-specific cell linker and other genetically engineered forms. The nanobody can be further extended into a drug coupling form. The product of the application can be used for mediating directional recognition and killing of TACI positive cells, and can be used as a supplement and expansion of BCMA targeted therapy, and provides a new candidate technical scheme for targeted therapy of multiple myeloma and other TACI related diseases.

The application relates to a traditional Chinese medicine composition and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The application provides a traditional Chinese medicine composition which comprises the following components in parts by weight: atractylodes 18-30 parts, luffa retinervus 12-20 parts, black tiger 12-20 parts, incarvillea 12-20 parts, caesalpinia 12-20 parts, astragalus 12-20 parts and silkworm excrement 6-10 parts. The traditional Chinese medicine composition is prepared by matching atractylodes, luffa retinervus, black tiger, incarvillea, caesalpinia, astragalus and silkworm excrement, the efficacy of eliminating phlegm and dampness, removing stasis and toxin, dredging blood vessels, nourishing blood, relieving pain and stopping numbness is strengthened, and the excessive pungent, warm and dry heat of the whole prescription is prevented. The traditional Chinese medicine composition is suitable for relieving numbness, pain and fatigue of tumor patients in the whole process of chemotherapy, targeted therapy and immunotherapy.

A deployment system for accurate placement of localization tags within biological tissue is disclosed. The system comprises a catheter hub with sheath, a stylet, and a loader. The catheter hub provides an interface for system components, while the flexible sheath allows navigation to target sites. The stylet, operable in multiple positions, guides the sheath and assists in tag deployment. The loader houses the localization tag and acts as a safety spacer during deployment. The system is compatible with endoscopes and various imaging modalities, offering improved accuracy and efficiency over traditional wire localization techniques. The localization tags may be passive or active, with potential for advanced functionalities such as biosensing or drug delivery. This minimally invasive system finds applications in tumor marking, lymph node localization, and targeted therapy delivery across multiple medical specialties.

This invention belongs to the field of biopharmaceutical technology, and specifically relates to the application of D724-0491 in the preparation of products for the prevention and treatment of breast cancer. D724-0491 inhibits the binding of HBXIP and KEAP1, reduces the level of NRF2 nuclear translocation, thereby inducing oxidative stress in tumor cells and promoting cancer cell death. It is a novel targeted therapy drug for breast cancer, improving the prognostic survival rate of breast cancer patients.

The application discloses an inhibitor for inhibiting KRAS phase separation to play an anti-tumor role and application, and relates to the fields of tumor molecular biology and targeted therapy.The application aims at solving the problems of limited effect, strong drug resistance and limited application range of KRAS tumor treatment methods, and the inhibitor is a statin.The KRAS protein can form a liquid condensate in cells, and the application discloses the mechanism of the KRAS protein in promoting KRAS protein processing, transportation and downstream signal activation, and further provides a technical scheme for inhibiting tumor growth and enhancing the therapeutic effect of a KRAS inhibitor by inhibiting the formation of KRAS condensates, so as to provide a new target and intervention approach for tumor treatment.

The invention discloses difunctional nano drug-loaded eye drops for xerophthalmia and a preparation method of the difunctional nano drug-loaded eye drops, and belongs to the field of pharmaceutical preparation technologies and ophthalmology pharmacy. The core of the invention is to construct a composite nanoparticle which has a core-shell structure and has long-acting adhesion lubrication and targeted control drug release functions. The preparation method comprises the following steps: firstly, encapsulating a hydrophobic immunosuppressant such as cyclosporine A in a biodegradable pad polymer matrix such as polylactic acid-glycolic acid copolymer (PLGA) by an emulsification-solvent evaporation method to form a drug-loaded polymer nano core; through the exquisite integrated design of the structure and the function, collaborative targeted therapy of two core pathological links of'tear film instability 'and'immune inflammation' of xerophthalmia is achieved, the bioavailability of the medicine is remarkably improved, the medication frequency and eye irritation are reduced, and the curative effect of xerophthalmia is improved. A more efficient and safer administration scheme with better patient compliance is provided for clinical treatment of xerophthalmia.

This invention relates to the field of traditional Chinese medicine technology, specifically to a compound traditional Chinese medicine preparation for treating liver cancer, made from the following herbs: cinnamon twig, schisandra fruit, inula flower, immature bitter orange, peony root, scutellaria root, rhubarb, turtle shell, physalis, and wisteria vine. The weight ratio of the above herbs is as follows: cinnamon twig 9g-15g, schisandra fruit 12g-18g, inula flower 9g-15g, immature bitter orange 9g-15g, peony root 12g-30g, scutellaria root 9g-15g, rhubarb 3g-9g, turtle shell 15g-45g, physalis vine 15g-30g, and wisteria vine 15g-30g. This invention can significantly improve symptoms such as hypochondriac pain, poor appetite, depression, abdominal distension, and bitter taste in the mouth, reduce the damage to the digestive system function caused by targeted therapy, improve the quality of life for patients, reduce toxicity and increase efficacy, lower treatment costs, and prolong patient life.

The present disclosure relates to collagen binding modification engineering of anti-inflammatory agents using collagen binding peptides (CBP) and vWF A3 to achieve targeted therapy of inflammatory diseases. Accordingly, embodiments of the present disclosure relate to compositions comprising an anti-inflammatory agent operably linked to an extracellular matrix (ECM) affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to serum proteins and / or ECM affinity peptides. Other aspects of the present disclosure relate to methods for treating an autoimmune or inflammatory disorder in a subject comprising administering to the subject a composition of the present disclosure.

This invention discloses a chimeric guide RNA integrating RNA interference and CRISPR-Cas13d and its applications. Utilizing the structural matching between shRNA and Cas13d crRNA, this invention embeds the complete Cas13d crRNA into the classic shRNA backbone, constructing a dual-pathway synergistic silencing chimeric guide RNA (SS-Rx). Experiments have demonstrated that SS-Rx possesses the dual activity of shRNA and CRISPR-Cas13d, exhibiting superior gene silencing efficiency compared to traditional RNA silencing tools, and can inhibit the proliferation, migration, and invasion of bladder cancer cells by suppressing tumor-related genes. This invention synergistically combines the advantages of RNA interference and CRISPR-Cas13d, providing an efficient and widely applicable framework for gene function research and RNA-targeted therapy, with significant economic benefits and broad application prospects.

The application belongs to the field of pharmacy, and particularly relates to a whole-process targeting polypeptide molecule with the functions of targeting brain capillary endothelial cells, tumor neovascular endothelial cells, tumor pseudo vascular, tumor cells and tumor stem cells, a stable and optimized polypeptide molecule, and a modified complex and drug delivery system for tumor diagnosis and treatment. The application prepares a whole-process targeting polypeptide WVAP and a WVAP modified drug and high polymer carrier material, and applies the WVAP to the construction of a drug delivery system for tumor imaging and targeted therapy. The results show that the WVAP can cross the blood-brain barrier, target tumor neovascular and cross the blood-tumor barrier, target tumor pseudo vascular, tumor cells and tumor stem cells; and the nano drug delivery system constructed by the WVAP modified high polymer carrier material can effectively deliver the loaded drug to the brain, target tumor tissues, and significantly improve the anti-tumor efficacy.

The present invention relates to an anti-PTK7 antibody and a use thereof. The anti-PTK7 antibody according to the present invention was found to inhibit angiogenesis, as well as the growth, migration, and invasion of human umbilical vein endothelial cells (HUVECs). Additionally, it effectively suppresses tumor growth in vivo, making it a promising therapeutic agent for angiogenesis-related diseases and PTK7-positive cancers. The antibody also has potential for further development as a targeted therapy for intractable cancers, positioning it as a key global therapeutic agent. Furthermore, the antibody can be humanized for clinical applications and serve as a critical component in the development of novel therapeutics.